Farnham INC. Medication assisted treatment - prescription drug and opioid addiction expansion project. - project name: farnham INC

Medication assisted treatment - prescription drug and opioid addiction expansion project farnham INC. Will partner with confidential help for alcohol drugs (CHAD), to enhance and expand medication-assisted treatment (mat) services in oswego and cayuga counties. Services will center around engagement, treatment and recovery supports for persons with OUD. This project will improve access to mat and strengthen retention to decrease illicit opioid drug use and prescribed opioid misuse resulting in decreased risk of fatal overdoses. Services will include outreach & engagement (O & E), treatment, and retention & follow up. This project will serve individuals with an opioid use disorder (OUD) seeking or receiving mat. The geographical catchment area (GCA) encompasses the entirety of cayuga and oswego counties, new york state (NYS). The counties are 2 of 62 in NYS and are sizeable rural areas. The GCA is bordered to the north by lake ontario and reaches west to the finger lakes region in central NY covering 1,815 square miles. The project will address the needs of the communities which includes high levels of OUD and overdoses, high relapse and low retention rates, high level of CO-occurring disorders, limited availability & access to services, high rates of tobacco use, rural, disconnected community (transportation barriers), lack of mat, unemployment rates, high levels of poverty, associated with OUD and is essential to meet these identified needs of the geographical catchment area and population of focus. This project will improve access to mat and treatment services, strengthen retention and foster connections to wrap around supports. This will be accomplished through achieving the project goals which include: (1) increase the number of individuals with OUD receiving mat, and (2) decrease illicit opioid drug use and prescription opioid misuse by program participants. The measurable objectives in meeting these goals include but are not limited to; 650 individuals access mat using at least one of the FDA-approved medications for the treatment of OUD as evidenced by treatment records, 85% of admitted individuals achieve 3-month and 70% achieve 6-month retention in treatment as evidenced by treatment records, 68% of admitted clients will have discontinued illicit drug use and prescription opioid misuse as evidenced by toxicology reports and treatment record, 75% of admitted patients participate in recovery supports as evidenced by program records, 100% of admitted patients will be assessed for tobacco cessation & 25% will achieve abstinence from tobacco as evidenced by toxicology screens. As a result of these grant funds this project will serve 100 individuals in year one, with 175 served in year two and 125 in each subsequent year, serving 650 unduplicated individuals over the course of the 5-year project.